Table 3 The risk factors with recurrence of mCNV
Variable | Sub-group | Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|---|---|
P value | HR | 95% CI for HR | P value | HR | 95% CI for HR | ||||
5% | 95% | 5% | 95% | ||||||
Subfoveal choroidal thickness | 10–50 μm (47.1%) | 0.0496 | 1.000 | – | – | 0.034 | 1.000 | – | – |
51–110 μm (52.9%) | 2.526 | 1.002 | 6.371 | 0.368 | 0.146 | 0.928 | |||
Neovascular signal around PSV | Absence (60.8%) | 0.038 | 1.000 | – | – | 0.026 | 1.000 | – | – |
Presence (39.2%) | 2.705 | 1.057 | 6.922 | 2.904 | 1.134 | 7.436 | |||
Anti-VEGF | Conbercept (45.1%) | 0.266 | 1.000 | – | – | – | – | – | – |
Ranibizumab (54.9%) | 1.658 | 0.68 | 4.043 | – | – | – | – | ||
Lacquer cracks | Absence (68.6%) | 0.116 | 1.000 | – | – | – | – | – | – |
Presence (31.4%) | 2.034 | 0.839 | 4.930 | – | – | – | – | ||
Baseline CNV area | < 0.3 mm2 (37.3%) | 0.089 | 1.000 | – | – | – | – | – | – |
0.3–0.7 mm2 (33.3%) | 3.007 | 1.016 | 8.899 | – | – | – | – | ||
> 0.7 mm2 (29.4%) | 1.081 | 0.328 | 3.565 | – | – | – | – | ||
Baseline BCVA | 0.005–0.5 logMAR (31.4%) | 0.943 | 1.000 | – | – | – | – | – | – |
0.5–1.0 logMAR (43.1%) | 1.191 | 0.423 | 3.357 | – | – | – | – | ||
1.0–2.0 logMAR (25.5%) | 1.062 | 0.323 | 3.485 | – | – | – | – | ||